<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34322850</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>04</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2190-3948</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>12</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Drug delivery and translational research</Title>
          <ISOAbbreviation>Drug Deliv Transl Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis.</ArticleTitle>
        <Pagination>
          <StartPage>1445</StartPage>
          <EndPage>1454</EndPage>
          <MedlinePgn>1445-1454</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s13346-021-01022-4</ELocationID>
        <Abstract>
          <AbstractText>Studies have suggested imatinib mesylate (ImM) as a potential treatment for systemic lupus erythematosus nephritis (SLEN). However, ImM has limited renal excretion. The goal of the current research was to develop an ImM containing nanoformulation, conduct studies to evaluate pharmacokinetics, and determine whether kidney deposition can be enhanced in a mouse model of SLEN. A fish oil-based ImM oil-in-water nanoemulsion was developed and characterized for particle size, zeta potential, pH, and stability. MRL/MpJ-Faslrp (model of SLEN) and MRL/MpJ (control) mice (12-13 weeks) received one dose of ImM as either a nanoemulsion or naked drug. Pharmacokinetics and kidney deposition studies were performed. Statistics were conducted with a student's T-test. The nanoemulsion characteristics included particle size range of 60-80 nm, zeta potential of -6.6 to -7.8 mV, polydispersity index &lt; 0.3, 3-day stability at 4 °C, and limited ImM leakage from the nanoemulsion in serum. Pharmacokinetics of the nanoformulation showed changes to pharmacokinetic parameters suggesting reduced systemic exposures (with reduced potential for toxicities) to ImM. Kidney deposition of ImM was threefold higher after 4 h in the MRL/MpJ-Faslrp mice that received the nanoformulation vs. naked drug. The current study showed encouraging results for development of a stable and well-characterized nanoemulsion for optimizing kidney deposition of ImM. Future strategies will define dose-efficacy and dose-toxicity relationships and evaluate approaches to further enhance kidney delivery and optimize deposition to the mesangial location of the kidney.</AbstractText>
          <CopyrightInformation>© 2021. Controlled Release Society.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Fogueri</LastName>
            <ForeName>Uma</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Charkoftaki</LastName>
            <ForeName>Georgia</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Roda</LastName>
            <ForeName>Gavriel</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tuey</LastName>
            <ForeName>Stacey</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ibrahim</LastName>
            <ForeName>Mustafa</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Persaud</LastName>
            <ForeName>Indushekhar</ForeName>
            <Initials>I</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wempe</LastName>
            <ForeName>Michael F</ForeName>
            <Initials>MF</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Brown</LastName>
            <ForeName>Jared M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Thurman</LastName>
            <ForeName>Joshua M</ForeName>
            <Initials>JM</Initials>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Division of Renal Diseases and Hypertension, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anchordoquy</LastName>
            <ForeName>Thomas J</ForeName>
            <Initials>TJ</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Joy</LastName>
            <ForeName>Melanie S</ForeName>
            <Initials>MS</Initials>
            <AffiliationInfo>
              <Affiliation>Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA. Melanie.Joy@cuanschutz.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Medicine, Division of Renal Diseases and Hypertension, University of Colorado, Aurora, CO, USA. Melanie.Joy@cuanschutz.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>07</Month>
          <Day>28</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Drug Deliv Transl Res</MedlineTA>
        <NlmUniqueID>101540061</NlmUniqueID>
        <ISSNLinking>2190-393X</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>8A1O1M485B</RegistryNumber>
          <NameOfSubstance UI="D000068877">Imatinib Mesylate</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000068877" MajorTopicYN="N">Imatinib Mesylate</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Hyperspectral imaging</Keyword>
        <Keyword MajorTopicYN="N">Imatinib</Keyword>
        <Keyword MajorTopicYN="N">Kidney deposition</Keyword>
        <Keyword MajorTopicYN="N">Lupus nephritis</Keyword>
        <Keyword MajorTopicYN="N">Nanoformulation</Keyword>
        <Keyword MajorTopicYN="N">Pharmacokinetics</Keyword>
        <Keyword MajorTopicYN="N">Tyrosine kinase inhibitor</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>6</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>30</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>7</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34322850</ArticleId>
        <ArticleId IdType="doi">10.1007/s13346-021-01022-4</ArticleId>
        <ArticleId IdType="pii">10.1007/s13346-021-01022-4</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Brinks R, Landwehr S, Fischer-Betz R, Schneider M, Giani G. Lexis diagram and illness-death model: simulating populations in chronic disease epidemiology. PLoS One. 2014;9(9):e106043.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0106043</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Munroe ME, James JA. Genetics of lupus nephritis: clinical implications. Semin Nephrol. 2015;35(5):396–409.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.semnephrol.2015.08.002</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brinks R, Fischer-Betz R, Sander O, Richter JG, Chehab G, Schneider M. Age-specific prevalence of diagnosed systemic lupus erythematosus in Germany 2002 and projection to 2030. Lupus. 2014;23(13):1407–11.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0961203314540352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Contreras G, Lenz O, Pardo V, et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int. 2006;69(10):1846–51.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.ki.5000243</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo L, Luo S, Du Z, et al. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nat Commun. 2017;8(1):878.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-00834-8</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maroz N, Segal MS. Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/MAJ.0b013e31827f4ee3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bagavant H, Kalantarinia K, Scindia Y, Deshmukh U. Novel therapeutic approaches to lupus glomerulonephritis: translating animal models to clinical practice. Am J Kidney Dis. 2011;57(3):498–507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.ajkd.2010.10.052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum. 2012;64(4):1215–26.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.34359</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karim MY, Alba P, Cuadrado MJ, et al. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology (Oxford). 2002;41(8):876–82.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/rheumatology/41.8.876</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zoja C, Corna D, Rottoli D, Zanchi C, Abbate M, Remuzzi G. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 2006;70(1):97–103.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/sj.ki.5001528</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sadanaga A, Nakashima H, Masutani K, et al. Amelioration of autoimmune nephritis by imatinib in MRL/lpr mice. Arthritis Rheum. 2005;52(12):3987–96.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/art.21424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iyoda M, Shibata T, Wada Y, et al. Long- and short-term treatment with imatinib attenuates the development of chronic kidney disease in experimental anti-glomerular basement membrane nephritis. Nephrol Dial Transplant. 2013;28(3):576–84.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ndt/gfs414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuckerman JE, Davis ME. Targeting therapeutics to the glomerulus with nanoparticles. Adv Chronic Kidney Dis. 2013;20(6):500–7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.ackd.2013.06.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zuckerman JE, Gale A, Wu P, Ma R, Davis ME. siRNA delivery to the glomerular mesangium using polycationic cyclodextrin nanoparticles containing siRNA. Nucleic Acid Ther. 2015;25(2):53–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/nat.2014.0505</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao J, Hayashi K, Horikoshi S, Ushijima H, Kimura J, Tomino Y. Effect of steroid-liposome on immunohistopathology of IgA nephropathy in ddY mice. Nephron. 2001;89(2):194–200.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000046067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shimizu H, Hori Y, Kaname S, et al. siRNA-based therapy ameliorates glomerulonephritis. J Am Soc Nephrol. 2010;21(4):622–33.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1681/ASN.2009030295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams RM, Jaimes EA, Heller DA. Nanomedicines for kidney diseases. Kidney Int. 2016;90(4):740–5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.kint.2016.03.041</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rottman JB, Willis CR. Mouse models of systemic lupus erythematosus reveal a complex pathogenesis. Vet Pathol. 2010;47(4):664–76.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/0300985810370005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shannahan JH, Podila R, Brown JM. A hyperspectral and toxicological analysis of protein corona impact on silver nanoparticle properties, intracellular modifications, and macrophage activation. Int J Nanomedicine. 2015;10:6509–21.</Citation>
        </Reference>
        <Reference>
          <Citation>DrugBank Online. https://www.drugbank.ca/drugs/DB00619 . Accessed on 1 Aug 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997;51(4):1188–95.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ki.1997.162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Singh R, Lillard JW Jr. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86(3):215–23.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexmp.2008.12.004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Williams RM, Shah J, Ng BD, et al. Mesoscale nanoparticles selectively target the renal proximal tubule epithelium. Nano Lett. 2015;15(4):2358–64.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/nl504610d</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdulrazaq M, Innes JK, Calder PC. Effect of omega-3 polyunsaturated fatty acids on arthritic pain: A systematic review. Nutrition. 2017;39–40:57–66.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nut.2016.12.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calder PC. Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochem Soc Trans. 2017;45(5):1105–15.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BST20160474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Calder PC, Bosco N, Bourdet-Sicard R, et al. Health relevance of the modification of low grade inflammation in ageing (inflammageing) and the role of nutrition. Ageing Res Rev. 2017;40:95–119.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arr.2017.09.001</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
